Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17596189 | 1.00 | P2RX7 (0.65) | P2RX7 | |
| SCHEMBL17595653 | 0.90 | P2RX7 (0.67) | P2RX7 | |
| SCHEMBL17595654 | 0.90 | P2RX7 (0.67) | P2RX7 | |
| SCHEMBL17596206 | 0.90 | P2RX7 (0.81) | P2RX7 | |
| SCHEMBL17596204 | 0.90 | P2RX7 (0.81) | P2RX7 | |
| SCHEMBL17596307 | 0.86 | P2RX7 (0.82) | P2RX7 | |
| SCHEMBL17596305 | 0.86 | P2RX7 (0.82) | P2RX7 | |
| SCHEMBL17596257 | 0.85 | P2RX7 (0.60) | P2RX7 | |
| SCHEMBL17596256 | 0.85 | P2RX7 (0.60) | P2RX7 | |
| SCHEMBL17596274 | 0.84 | P2RX7 (0.60) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191488-B1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-14 | — | — | EP | claimed |
| EP-3191488-A1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | Janssen Pharmaceutica, N.V. (BE) | 2017-07-19 | — | — | EP | claimed |
| WO-2016039983-A1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-17 | — | — | WO | claimed |
| EP-3191488-B1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-14 | — | — | EP | disclosed |
| US-20180118749-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118749-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| EP-3191488-A1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | Janssen Pharmaceutica, N.V. (BE) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016039983-A1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118749-A1 | P2X7 MODULATORS | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.